JP2017506662A5 - - Google Patents

Download PDF

Info

Publication number
JP2017506662A5
JP2017506662A5 JP2016554571A JP2016554571A JP2017506662A5 JP 2017506662 A5 JP2017506662 A5 JP 2017506662A5 JP 2016554571 A JP2016554571 A JP 2016554571A JP 2016554571 A JP2016554571 A JP 2016554571A JP 2017506662 A5 JP2017506662 A5 JP 2017506662A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
coxsackievirus
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016554571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506662A (ja
JP6857498B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2015/000111 external-priority patent/WO2015127501A1/en
Publication of JP2017506662A publication Critical patent/JP2017506662A/ja
Publication of JP2017506662A5 publication Critical patent/JP2017506662A5/ja
Application granted granted Critical
Publication of JP6857498B2 publication Critical patent/JP6857498B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016554571A 2014-02-27 2015-02-27 癌を処置するための併用方法 Expired - Fee Related JP6857498B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014900647A AU2014900647A0 (en) 2014-02-27 Combination method for treatment of cancer
AU2014900647 2014-02-27
PCT/AU2015/000111 WO2015127501A1 (en) 2014-02-27 2015-02-27 Combination method for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021001547A Division JP2021063120A (ja) 2014-02-27 2021-01-07 癌を処置するための併用方法

Publications (3)

Publication Number Publication Date
JP2017506662A JP2017506662A (ja) 2017-03-09
JP2017506662A5 true JP2017506662A5 (enExample) 2020-05-21
JP6857498B2 JP6857498B2 (ja) 2021-04-14

Family

ID=54008051

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016554571A Expired - Fee Related JP6857498B2 (ja) 2014-02-27 2015-02-27 癌を処置するための併用方法
JP2021001547A Pending JP2021063120A (ja) 2014-02-27 2021-01-07 癌を処置するための併用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021001547A Pending JP2021063120A (ja) 2014-02-27 2021-01-07 癌を処置するための併用方法

Country Status (9)

Country Link
US (3) US20170000832A1 (enExample)
EP (2) EP3441084A1 (enExample)
JP (2) JP6857498B2 (enExample)
KR (1) KR102407019B1 (enExample)
CN (1) CN107073099B (enExample)
AU (2) AU2015222685A1 (enExample)
CA (1) CA2940570A1 (enExample)
SG (2) SG11201607130RA (enExample)
WO (1) WO2015127501A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008007056A (es) 2005-12-02 2008-11-12 Sinai School Medicine Virus quimericos que presentan proteinas de superficie no nativas y usos de los mismos.
KR102222157B1 (ko) 2013-03-14 2021-03-03 이칸 스쿨 오브 메디슨 엣 마운트 시나이 뉴캐슬병 바이러스 및 이의 용도
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
WO2015127501A1 (en) * 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
US10744170B2 (en) * 2015-10-15 2020-08-18 Duke University Combination treatment
ES2919953T3 (es) 2016-01-27 2022-07-29 Oncorus Inc Vectores víricos oncolíticos y usos de los mismos
CN109983121A (zh) 2016-06-30 2019-07-05 昂克诺斯公司 治疗性多肽的假型化溶瘤病毒递送
US20190275092A1 (en) * 2016-11-01 2019-09-12 Dnatrix, Inc. Combination therapy for treatment of brain cancers
EP3606549A1 (en) * 2017-04-07 2020-02-12 Hookipa Biotech GmbH Arenavirus particles to treat solid tumors
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
RU2771110C2 (ru) 2017-07-26 2022-04-26 Онкорус, Инк. Онколитические вирусные векторы и их применение
CN109576231B (zh) * 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
US20210169957A1 (en) * 2018-08-17 2021-06-10 Virocure, Inc. Combined use of squirrel poxvirus and myxoma poxvirus, for treating cancer
US11230189B2 (en) 2019-03-29 2022-01-25 Honda Motor Co., Ltd. System and method for application interaction on an elongated display screen
EP4077644A1 (en) 2019-12-20 2022-10-26 Merck Sharp & Dohme LLC Purified compositions of enteroviruses and methods of purification with glutathione affinity chromatography

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3806565A1 (de) 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
DE3922444A1 (de) 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5786199A (en) 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
PT696326E (pt) 1993-04-30 2003-08-29 Wellstat Biologics Corp Utilizacao de ndv no fabrico de um medicamento para tratamento do cancro
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
CA2230033C (en) 1995-09-27 2010-01-26 Peter L. Collins Production of infectious respiratory syncytial virus from cloned nucleotide sequences
CA2231603C (en) 1995-10-17 2009-04-21 Wayne State University Chicken interleukin-15 and uses thereof
EP0912724B1 (en) 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
BR9712138A (pt) 1996-09-27 2000-01-18 American Cyanamid Co Vìrus de rna isolado, vacina, processo para imunizr um indivìduo para induzir proteção contra um vìrus de rna não segmentado, sentido negativo, de filamento único, da ordem mononegavirales e para produzir vìrus de rna, molécula de ácido nucleico isolada e composição.
DE69842165D1 (de) 1997-05-23 2011-04-21 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen
ES2287977T3 (es) 1997-07-11 2007-12-16 Yale University Rabdovirus con cubiertas rediseñadas.
JP2001517448A (ja) 1997-09-19 2001-10-09 アメリカン・サイアナミド・カンパニー 弱毒化呼吸合胞体ウイルス
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
NZ503664A (en) 1997-10-09 2002-08-28 Pro Virus Inc A method for purifying an RNA virus comprising generating a clonal virus and purifying the clonal virus by ultracentrifugation without pelleting
JP4837827B2 (ja) 1998-06-12 2011-12-14 マウント シナイ スクール オブ メディシン 新規なウイルス増殖方法およびそのためのインターフェロン欠損培養基
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US7052685B1 (en) 1998-10-15 2006-05-30 Trustees Of The University Of Pennsylvania Methods for treatment of cutaneous T-cell lymphoma
NZ550861A (en) 1999-04-15 2009-03-31 Wellstat Biologics Corp Treatment of neoplasms with viruses
US20030224017A1 (en) 2002-03-06 2003-12-04 Samal Siba K. Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
US7244558B1 (en) 1999-05-05 2007-07-17 University Of Maryland Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated Newcastle disease vaccines
DE122007000070I1 (de) 1999-07-14 2008-01-31 Sinai School Medicine In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren
AU7607900A (en) 1999-09-22 2001-04-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
US6896881B1 (en) 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
EP1248654B1 (en) 2000-01-20 2005-10-05 Universität Zürich Institut für Medizinische Virologie Intra-tumoral administration of il-12 encoding naked nucleic acid molecules
WO2001077394A1 (en) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US6818444B2 (en) 2000-08-04 2004-11-16 Heska Corporation Canine and feline proteins, nucleic acid molecules and uses thereof
US7740863B2 (en) 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
WO2002102404A1 (en) 2001-06-18 2002-12-27 Institut National De La Recherche Agronomique Uses of cytokines
WO2003092579A2 (en) 2002-04-29 2003-11-13 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
WO2003102183A1 (en) 2002-06-03 2003-12-11 Dnavec Research Inc. Pramyxovirus vectors encoding antibody and utilization thereof
US7971030B2 (en) 2002-08-07 2011-06-28 Mmagix Technology Limited Method for using multiple processing resources which share multiple co-processor resources
SE0203159D0 (sv) 2002-10-25 2002-10-25 Electrolux Ab Handtag till ett motordrivet handhållet verktyg
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
ES2367027T3 (es) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
AU2005221725B2 (en) 2004-03-11 2010-06-24 Viralytics Limited Modified oncolytic viruses
EP1793851B1 (en) * 2004-08-20 2016-10-05 Viralytics Limited Methods and compositions for treatment of hematologic cancers
CN101065144B (zh) * 2004-08-20 2012-06-13 溶瘤病毒有限公司 治疗血液癌症的方法和组合物
EP2292246A1 (en) 2004-11-12 2011-03-09 Bayer Schering Pharma Aktiengesellschaft Recombinant Newcastle Disease Virus
WO2006074526A1 (en) 2005-01-17 2006-07-20 Viralytics Limited Method and composition for treatment of neoplasms
PL1899364T5 (pl) 2005-05-17 2024-12-09 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
WO2007008918A2 (en) 2005-07-08 2007-01-18 Wayne State University Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
AU2006287052B2 (en) * 2005-08-31 2009-03-12 Oncolytics Biotech Inc. Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
MX2008007056A (es) 2005-12-02 2008-11-12 Sinai School Medicine Virus quimericos que presentan proteinas de superficie no nativas y usos de los mismos.
EP1984505B1 (en) 2006-01-13 2019-12-25 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US20090175826A1 (en) 2006-06-05 2009-07-09 Elankumaran Subbiah Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same
WO2008011726A1 (en) 2006-07-27 2008-01-31 Ottawa Health Research Institute Staged immune-response modulation in oncolytic therapy
EP3293266B1 (en) 2007-05-04 2025-12-24 University Health Network Il-12 immunotherapy for cancer
DK2160401T3 (da) 2007-05-11 2014-10-20 Altor Bioscience Corp Fusionsmolekyler og il-15-varianter
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 pd-1에 대한 항체
CA2691785C (en) 2007-06-27 2017-01-10 Marine Polymer Technologies Inc. Complexes of il-15 and il-15ralpha and uses thereof
EP2085092A1 (en) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
CN101787373B (zh) 2009-01-23 2013-06-19 中国人民解放军第二军医大学东方肝胆外科医院 一种携带外源基因在包装细胞中高效生产的重组病毒载体、其构建方法及其用途
WO2010091262A1 (en) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Chimeric newcastle disease viruses and uses thereof
AU2010241864B2 (en) 2009-04-30 2014-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
US20100297072A1 (en) * 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
EP3135294B1 (en) 2009-08-14 2020-06-03 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Use of il-15-il-15 receptor heterodimers to treat lymphopenia
CN105331633A (zh) 2009-08-21 2016-02-17 梅里亚有限公司 重组禽副粘病毒疫苗及其制备和使用方法
CN104826106B (zh) 2009-09-30 2019-01-11 斯隆凯特林防癌纪念中心 用于治疗癌症的组合免疫疗法
US10238734B2 (en) 2010-03-23 2019-03-26 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
WO2012000188A1 (en) 2010-06-30 2012-01-05 Tot Shanghai Rd Center Co., Ltd. Recombinant tumor vaccine and method of producing such
EP2619229B1 (en) 2010-09-21 2016-04-06 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
CN114262690A (zh) 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
CA2850575C (en) 2011-10-11 2020-12-15 Universitat Zurich Prorektorat Mnw Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
DK2806883T3 (da) * 2012-01-25 2019-07-22 Dnatrix Inc Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation
EP2669381A1 (en) 2012-05-30 2013-12-04 AmVac AG Method for expression of heterologous proteins using a recombinant negative-strand RNA virus vector comprising a mutated P protein
US20150250837A1 (en) 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
WO2014066527A2 (en) 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
KR102222157B1 (ko) 2013-03-14 2021-03-03 이칸 스쿨 오브 메디슨 엣 마운트 시나이 뉴캐슬병 바이러스 및 이의 용도
KR102539359B1 (ko) 2013-04-19 2023-06-02 싸이튠 파마 감소된 혈관 누출 증후군에 대한 사이토카인 유도체 치료
CA2915397A1 (en) 2013-06-17 2014-12-24 Viralytics Limited Methods for the treatment of bladder cancer
SI3030262T1 (sl) 2013-08-08 2020-03-31 Cytune Pharma Kombiniran farmacevtski sestavek
CA2919725C (en) 2013-08-08 2023-04-18 Cytune Pharma An il-15 and il-15r.aplha. sushi domain based modulokines
KR102310692B1 (ko) 2013-09-03 2021-10-12 메디뮨 리미티드 약독화된 뉴캐슬병 바이러스를 특징으로 하는 조성물 및 신생물을 치료하기 위한 사용 방법
WO2015127501A1 (en) * 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
WO2016018920A1 (en) 2014-07-29 2016-02-04 Admune Therapeutics Llc Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
WO2016048903A1 (en) 2014-09-22 2016-03-31 Intrexon Corporation Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
EP3230498B1 (en) 2014-12-09 2023-01-18 Merck Sharp & Dohme LLC System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
CN106166294A (zh) 2015-05-18 2016-11-30 国科丹蓝生物科技(北京)有限公司 一种用于术前介入放疗治疗肿瘤的化合物
US10344067B2 (en) 2016-02-25 2019-07-09 Deutsches Krebsforschungszentrum RNA viruses expressing IL-12 for immunovirotherapy
CN105734023B (zh) 2016-03-28 2019-04-26 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒在制备抗肝癌药物中的应用

Similar Documents

Publication Publication Date Title
Dillon et al. PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours
Morris et al. Interaction of radiation therapy with molecular targeted agents
JP2021063120A5 (enExample)
JP6787792B2 (ja) がんの処置のための併用治療
Lange et al. A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma
Perry et al. Novel therapies in glioblastoma
RU2018135317A (ru) Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
JP7307044B2 (ja) 逐次的抗癌治療
Peled et al. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non–small-cell lung cancer
Middleton et al. Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid–inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors
Chen et al. Overview of tumor immunotherapy based on approved drugs
RU2016108809A (ru) Способы повышения форсированного объема выдоха у больных астмой с применением бенрализумаба
Taha et al. Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy
Eshun et al. VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy
Young et al. Ideal timing of immunotherapy with radiation in murine tumor models
RU2524309C1 (ru) Способ выбора тактики лечения местно-распространенного рака предстательной железы
Liu et al. Pirtobrutinib and venetoclax combination overcomes resistance to targeted and CAR Tcell therapy in aggressive mantle cell lymphoma
Kleinovink et al. Combination of Photodynamic Therapy and Immune Checkpoint Blockade
Wang et al. Preclinical safety assessment of an oncolytic herpes simplex virus type 2 expressed PD-L1/CD3 bispecific antibody
CN102363780A (zh) 靶向人cd147小分子rna干扰序列及其用途
Castro et al. EXTH-52. HARNESSING AB CELL THERAPY TO PROMOTE ANTI-GLIOBLASTOMA HUMORAL RESPONSE
Bebb et al. Don’t jump to rash conclusions
Cuiffo et al. LOCAL IMMUNOTHERAPY WITH INTASYL (TM) SELFDELIVERING RNAI TARGETING CTLA-4 PROVIDES ROBUST TUMOR CONTROL IN VIVO
Tosin et al. EXTH-48. INHIBITION OF SREBP-1 IS SYNTHETICALLY LETHAL WITH BCL-XL/BCL-2 INHIBITION IN GLIOBLASTOMA IN VITRO
Sardi et al. Drug penetration through the blood–brain barrier after radiotherapy: New approaches to bypass glioblastoma chemoresistance